JNPH

Volume 9 No. 1 (April 2021)

GENETIC IN CANCER: RB1 MUTATIONS IN RETINOBLASTOMA CASES

LISSABERTI AMALIAH, JIPRI SUYANTO
PEDIATRIC DEPARTEMENT, MOHAMMAD HOESIN GENERAL HOSPITAL, PALEMBANG, INDONESIA.
STUDY PROGRAM OF PUBLIC HEALTH, FACULTY OF HEALTH SCIENCE, DEHASEN UNIVERSITY, INDONESIA
Email: jefrisuyanto@gmail.com

ABSTRACT

Retinoblastoma (RB) is a uncommon childhood malignant ailment induced by means of the biallelic inactivation of RB1 gene. Early analysis and identification of carriers of heritable RB1 mutations can enhance sickness effect and management. In this study, mutational evaluation used to be performed on fifty-nine matched tumor and peripheral blood samples from 18 bilateral and forty one unilateral unrelated RB instances by means of a combinatorial strategy of Multiplex Ligation-dependent Probe Amplification (MLPA) assay, deletion screening, direct sequencing, replica wide variety gene dosage evaluation and methylation assays. Screening of each blood and tumor samples yielded a mutation detection charge of 94.9% (56/59) whilst solely 42.4% (25/59) of mutations had been detected if blood samples on my own had been analyzed. Biallelic mutations had been discovered in 43/59 (72.9%) of tumors screened. There have been three instances (5.1%) in which no mutations may want to be detected and germline mutations have been detected in 19.5% (8/41) of unilateral cases. A whole of sixty one factor mutations have been identified, of which 10 had been novel. There was once a excessive incidence of in the past stated recurrent mutations, taking place at 38.98% (23/59) of all cases. Of pastime had been three instances of mosaic RB1 mutations detected in the blood from sufferers with unilateral retinoblastoma. Our findings additionally underscore the significance of genetic checking out in aiding individualized disorder administration plans for sufferers and asymptomatic household individuals carrying low-penetrance, germline mosaicism or heritable unilateral mutational phenotypes.

Keywords: Genetic, Cancer, Retinoblastoma

INTRODUCTION

Retinoblastoma is a malignancy that most often affects children because two folds of the RB1 gene are missing. The world incidence of this disorder is 1 case in 15,000 to 20,000 stay births taking place equally amongst adult males and ladies. On a international scale, an estimated 3001 to 3376 young people die due to retinoblastoma yearly. The mortality charge in Asia (39%) is a good deal greater than that of Europe, Canada, and the USA (3–5%) [1] due to the hole in healthcare get entry to which mainly

refers to the truth that majority of RB sufferers are identified in low and center earnings countries, whereas the bulk of retinoblastoma-specific fitness care amenities are handy in excessive profits nations.

Most RB instances are recognized via 5 years of age and manifest in both heritable or non-heritable forms. Non-heritable RB arises from somatic mutations taking place on each alleles of RB1 gene in the growing retina, whereas heritable RB arises from the inheritance of at least one germline mutation alongside with an received RB1 somatic mutation. All bilateral retinoblastomas are heritable, of which about 10% are inherited. Fifteen percentage of unilateral retinoblastoma take place due to de novo germline RB1 mutations which is transmissible in subsequent generations [8]. In heritable RB, offspring have a 50% hazard of inheriting the mutant RB1 allele from an affected parent. Such an inheritance of the mutant RB1 allele outcomes in a 97% hazard of growing the disorder and a excessive lifelong chance of secondary cancers.

RB1 inactivation has been implicated in greater than 97% of all RB instances with mutations in this gene being undetectable in the final instances. Recent reviews endorse that different genes may also play a position in both using tumor initiation or development. It has been postulated that probably candidate genes might also be positioned in chromosomal areas with recurrent positive aspects and losses discovered in RB tumors. Rushlow et al furnished proof that retinoblastoma may want to also be triggered by using MYCN oncogene amplification and expected that 18% of instances who are identified with non-familial unilateral RB earlier than the age of 6 months would harbour solely MYCN amplification and no RB1 mutations. They additionally quoted some other 1.5% of unilateral non-familial RB whose pathogenesis should now not be defined as they harboured everyday RB1 and MYCN genes.

Genetic checking out in RB is necessary to now not solely pick out the spectrum of underlying mutations however additionally to delineate heritable RB for non-heritable ones for environment friendly genetic counselling. Hence, this find out about pursuits to represent the spectrum of RB1 mutations in RB instances viewed amongst sufferers in Singapore in order to useful resource ailment management.

MATERIAL AND METHODS

Patients

This learn about was once carried out on DNA samples from a cohort of fifty nine retinoblastoma instances (18 bilateral and forty one unilateral), amassed over a duration of 15 years. Diagnosis of retinoblastoma was once mounted by way of widespread ophthalmologic and histological criteria. Thirty-four instances had been girl and twenty-five have been male. When an RB1 mutation was once determined in the peripheral blood of the proband, DNA samples from the mother and father had been examined for presence of the recognized mutation. If dad and mom examined nice for the proband's mutation, siblings' blood have been accumulated and analysed similarly. In addition, parental DNA was once sought in instances the place a gross deletion in RB1 gene was once identified, to determine the parental starting place of the loss of RB1 allele. Samples from all sufferers and household individuals had been accumulated with written knowledgeable consent and in accordance with the ideas of the Declaration of Helsinki.

DNA isolation

DNA samples used have been extracted from matched peripheral blood (10ml in EDTA tubes) and sparkling tumor samples (100–200 mg), amassed after enucleation. DNA isolation protocol was once tailored from the excessive salt extraction approach of Miller et al.

RB1 gene sequencing

The DNA bought from all fifty nine tumors and corresponding blood samples was once sequenced for 27 exons and promoter place of RB1 gene after PCR amplification the use of 27 units of primers as described formerly. Some instances had been despatched out to an worldwide laboratory (Impact Genetics Inc., Canada) for RB1 gene sequence evaluation and Allele-specific PCR (AS-PCR) for eleven recurrent RB1 mutations. Additional data about RB1 gene mutations have been demonstrated from gene locus particular mutation database (rb1-lsdb) and The Human Gene Mutation Database (HGMD). Predictive evaluation equipment had been used to decide the pathogenicity popularity of novel variants.

Gross *RB1* deletions analysis

Multiplex ligation-dependent probe amplification (MLPA) analysis to display screen for deletions or duplications in the RB1 gene, MLPA evaluation was once carried out the use of the SALSA MLPA package P047-B1 RB1 (MRC-Holland, Amsterdam, the Netherlands) in accordance to the manufacturer's protocol with a hundred ng of genomic DNA from matched tumor and blood. The PCR amplicons have been seperated on Genetic Analyzer 3130 (Applied Biosystems, Foster City, CA), and the outcomes have been analyzed the use of Cofflalyser Software reachable at http://www.mlpa.com/coffalyser/. Based on the normalized sign price ratio of 1:1; threshold ratios of 0.75 (deletion) and 1.30 (duplication) have been used to point out loss or obtain of probe replica numbers respectively.

Microsatellite evaluation and SNP genotyping the extent of loss of heterozygosity (LOH) was once assayed in matched tumor and blood DNA the usage of 20 flanking extragenic microsatellite markers. Allelic imbalance affecting RB1 gene locus at 13q14 was once examined the usage of three intragenic microsatellites: D13S153—located inside intron two of RB1, dinucleotide repeats (TG) 22—located inside intron four and tetra nucleotide repeats (TTCT)16—located inside intron 20 of RB1 alongside with 4 beforehand stated SNP markers. The SNP markers and Microsatellite markers have been typed the usage of trendy PCR-based strategies as described formerly and samples had been scored as informative if the lymphocyte DNA confirmed heterozygosity of alleles for every marker, or non-informative for homozygosity or fine for LOH when the tumour confirmed entire loss of one allele. LOH used to be ascertained when loss of one of the alleles in the tumour samples used to be discovered whereas the matched lymphocyte pattern confirmed heterozygous alleles.

Methylation specific PCR (MSP)

Methylation evaluation at the CpG islands of RB1 Promoter in tumor and blood was once analyzed the use of CpGenomeTM DNA Modification package (Intergen) and methylation unique PCR the usage of precise primers as beforehand described. For MGMT promoter hypermethylation analysis, primers have been synthesized the use of Primo MSP 3.4 software program (http://www.changbioscience.com/primo/primom.html) based totally on MGMT promoter sequence (GenBank Acc. No. X61657). MSP used to be carried out in two separate reactions to perceive unmethylated and methylated DNA as described in the past. showed heterozygous alleles.

Quantitative multiplex PCR (QM-PCR)

QM-PCR research have been carried out on tumor samples to decide replica quantity of TNF (6p21.3) the use of techniques formerly described. A advantageous control, DNA from the WERI-RB1 retinoblastoma cellphone line which has isochromosome 6p (i6p) and therefore carrying four copies of the chromosomal place 6p, and a ordinary DNA as exterior manage used to be amplified

collectively with tumour samples in every PCR reaction.

Statistics

To decide variations in the frequencies of located kinds of RB1 factor mutations in our cohort and these from international mutation frequencies from a said meta-analysis by way of Valverde et al 2005, the χ2 goodness-of-fit take a look at was once performed. Fisher's precise t check used to be carried out to check the importance of all contingency tables in the study. Welch's t check used to be carried out to take a look at the importance of age distribution through one of a kind categories. P price of <0.05 used to be regarded significant.

RESULTS

Age at diagnosis

A summary of cases by using their respective clinicopathological traits When the age of sufferers with somatic factor mutations (25 unilateral cases) used to be in contrast to these with germline factor mutations (18 bilateral + 7 unilateral cases), the distribution was once discovered to be statistically considerable by using Welch's t take a look at of unpaired companies (Somatic group: imply age at analysis = 28.71 months, preferred deviation = 18.51 months; Germline group: suggest age at prognosis = 14.71, popular deviation = 11.46 months; p = 0.001824, 95% CI [-22.5448, -5.469]).

DISCUSSION

Mutations identified in *RB1*

Among the 118 RB1 alleles examined from the fifty nine RB cases, ninety eight mutant alleles have been recognized (83.05%) . The proportion of mutated alleles recognized inside the unilateral (81.70%) and bilateral (86.11%) cases . The kinds of RB1 mutations carried by using these alleles have been factor mutations, gross deletions and promoter methylation.

Spectrum of RB1 factor mutations complete of sixty one factor mutations have been recognized in 84.7% (50/59) of all our retinoblastoma cases. This comprised a hundred percent (18/18) of bilateral cases and 78% (32/41) of unilateral cases. The spectrum of extraordinary mutation kinds amongst the sixty one factor mutations were; nonsense mutations taking place at 55.7% (34/61), accompanied by using 24.6% (15/61) frameshift, 9.8% (6/61) splicing, 8.2% (5/61) missense and 1.64% (1/61) promoter modifications.

Overall, 42.4% (25/59) instances examined nice for RB1 mutations in the peripheral blood, which blanketed 24 instances with factor mutations and one case of gross deletion of germline origin. All however one bilateral tumor introduced with germline RB1 mutations (17/18; 94.4%). The ultimate one bilateral case had a single somatic factor mutation now not current in blood, which suggests the presence of some other germline RB1 mutation which used to be no longer detected via the techniques used in this study.Among the unilateral cases, 19.5% (8/41) had been said to harbour RB1 mutations in blood.

CONCLUSIONS

The spectrum of RB1 mutations and in addition emphasizes on the want to now not solely discover the causative mutations however additionally to discover extraordinary disorder phenotypes viz., low-penetrance mutations and germline mosaicism. Thus, our find out about on figuring out the genetic signatures from Singaporean sufferers with RB will similarly useful resource in growing splendid screening programmes and devising efficient sickness administration measures for such sufferers and their families.

SUGGESTION

I hope this manuscript can contribute to the development of research in the future.

Acknowledgment

We would like to thank researchers who have researched with good intentions and I hope this manuscript can contribute to the development of research in the future.

BIBLIOGRAPHY

Benavente CA, Dyer MA. Genetics and Epigenetics of Human Retinoblastoma. *Annu Rev Pathol Mech Dis*. 2015;10: 547–562. 10.1146/annurev-pathol-012414-040259 [PubMed] [CrossRef] [Google Scholar]

Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PBS, et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. *Genes Chromosom Cancer*. 2007;46: 118–129. 10.1002/gcc.20383 [PubMed] [CrossRef] [Google Scholar]

Bookstein R, Lai CC, Hoang T, Lee WH. PCR-based detection of a polymorphic BamHI site in intron 1 of the human retinoblastoma (RB) gene. *Nucleic Acids Res*. 1990;18: 1666 10.1093/nar/18.6.1666 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. *Cancer Res*. 1996;56: 3331–3337. Available: http://www.ncbi.nlm.nih.gov/pubmed/8764130 [PubMed] [Google Scholar]

Choy KW, Pang CP, To KF, Yu CBO, Ng JSK, Lam DSC. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues. *Investig Ophthalmol Vis Sci*. 2002;43: 1344–1349. Available: http://www.ncbi.nlm.nih.gov/pubmed/11980845 [PubMed] [Google Scholar]

Chen D, Gallie BL, Squire JA. Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. *Cancer Genet Cytogenet*. 2001;129: 57–63. 10.1016/S0165-4608(01)00427-7 [PubMed] [CrossRef] [Google Scholar]

Dimaras H, Kimani K, Dimba EAO, Gronsdahl P, White A, Chan HSL, et al. Retinoblastoma. *Lancet*. 2012;379: 1436–1440. 10.1016/S0140-6736(11)61137-9 [PubMed] [CrossRef] [Google Scholar]

Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. *Nat Rev Dis Prim*. 2015; 15062 10.1038/nrdp.2015.62 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. *Nat Rev Dis Prim*. 2015; 15062 10.1038/nrdp.2015.62 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. *Oncogene. University Children's Hospital of Essen, Universitätsklinikum Essen, D-45122 Essen, Germany, England*; 2005;24: 6441–6449. 10.1038/sj.onc.1208792 [PubMed] [CrossRef] [Google Scholar]

Hogg A, Onadim Z, Baird PN, Cowell JK. Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. *Oncogene*. 1992;7: 1445–1451.

Available: http://www.ncbi.nlm.nih.gov/pubmed/1352398 [PubMed] [Google Scholar]

Horsthemke B, Greger V, Becher R, Passarge E. Mechanism of i(6p) formation in retinoblastoma tumor cells. *Cancer Genet Cytogenet*. 1989;37: 95–102. 10.1016/0165-4608(89)90079-4 [PubMed] [CrossRef] [Google Scholar]

Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. *Br J Ophthalmol*. 2009;93: 1129–1131. 10.1136/bjo.2008.150292 [PubMed] [CrossRef] [Google Scholar]

Kooi IE, Mol BM, Massink MPG, De Jong MC, De Graaf P, Van Der Valk P, et al. A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression. *PLoS One. Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands*; 2016;11: e0153323 10.1371/journal.pone.0153323 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Laurie NA, Donovan SL, Shih C-S, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. *Nature. Nature Publishing Group*; 2006;444: 61–66. 10.1038/nature05194 [PubMed] [CrossRef] [Google Scholar]

Lim FPM, Soh SY, Iyer JV, Tan AM, Swati H, Quah BL. Clinical Profile, Management, and Outcome of Retinoblastoma in Singapore. *J Pediatr Ophthalmol Strabismus*. 2013;50: 106–112. 10.3928/01913913-20121211-01 [PubMed] [CrossRef] [Google Scholar]

Lohmann DR, Gallie BL. Retinoblastoma: Revisiting the model prototype of inherited cancer [Internet]. *American Journal of Medical Genetics*. 2004. pp. 23–28. 10.1002/ajmg.c.30024 [PubMed] [CrossRef] [Google Scholar]

Marchong MN, Chen D, Corson TW, Lee C, Harmandayan M, Bowles E, et al. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. *Mol Cancer Res*. 2004;2: 495–503. 2/9/495 [pii] [PubMed] [Google Scholar]

Mendoza PR, Grossniklaus HE. The Biology of Retinoblastoma. *Prog Mol Biol Transl Sci. Department of Ophthalmology, Emory University, School of Medicine, Atlanta, GA, United States*; 2015;134: 503–516. 10.1016/bs.pmbts.2015.06.012 [PubMed] [CrossRef] [Google Scholar]

Mol BM, Massink MPG, van der Hout AH, Dommering CJ, Zaman JMA, Bosscha MI, et al. High resolution SNP array profiling identifies variability in retinoblastoma genome stability. *Genes Chromosom Cancer. Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands*; 2014;53: 1–14. 10.1002/gcc.22111 [PubMed] [CrossRef] [Google Scholar]

McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, et al. Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis. *Cancer Cell. United States: NIH Public Access*; 2011;20: 260–275. 10.1016/j.ccr.2011.07.005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988;16: 1215 10.1093/nar/16.3.1215 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Mcgee TL, Cowley GS, Yandell DW, Dryja TP. Detection of the Xbal RFLP within the retinoblastoma locus by PCR. *Nucleic Acids Res*. 1990;18: 207 10.1093/nar/18.1.207-a [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Priya K, Jada SR, Boon LQ, Thuan CQ, Poh SL. High incidence of allelic loss at 16q12.2 region spanning RBL2/p130

gene in retinoblastoma. *Cancer Biol Ther. Division of Human Genetics, Department of Paediatrics, National University of Singapore, Singapore, Singapore: Taylor & Francis*; 2009;8: 714–717. 10.4161/cbt.8.8.7921 [CrossRef] [Google Scholar]

Rowland JS, Barton DE, Taylor GR. A comparison of methods for gene dosage analysis in HMSN type 1. *J Med Genet*. 2001;38: 90–5. 10.1136/jmg.38.2.90 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, et al. Characterisation of retinoblastomas without RB1 mutations: Genomic, gene expression, and clinical studies. *Lancet Oncol. Impact Genetics and the Toronto Western Hospital Research Institute, University Health Network, Toronto, ON, Canada*; 2013;14: 327–334. 10.1016/S1470-2045(13)70045-7 [PubMed] [CrossRef] [Google Scholar]

Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. *Cancer Res*. 1997;57: 2229–2237. Available: http://www.ncbi.nlm.nih.gov/pubmed/9187126 [PubMed] [Google Scholar]

Toguchida J, Ishizaki K, Sasaki MS. Mutation Spectrum of the Retinoblastoma Gene in Osteosarcomas. *Cancer Res*. 1994;54: 3042–3048. Available: http://www.ncbi.nlm.nih.gov/pubmed/8187094 [PubMed] [Google Scholar]

Vaughn GL, Toguchida J, Mcgee T, Dryja TP. Pcr detection of the Tth 111 I RFLP at the RB locus. *Nucleic Acids Res. Oxford University Press*; 1990;18: 4965 10.1093/nar/18.16.4965 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Yau SC, Bobrow M, Mathew CG, Abbs SJ. Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. *J Med Genet*. 1996;33: 550–8. 10.1136/jmg.33.7.550 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Zeschnigk M, Lohmann D, Horsthemke B. A PCR test for the detection of hypermethylated alleles at the retinoblastoma locus. *J Med Genet*. 1999;36: 793–4. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1734233&tool=pmcentrez&rendertype=abstract [PMC free article] [PubMed] [Google Scholar]